Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Wednesday, 30'th Aug 2023
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks
08:31am, Monday, 21'st Aug 2023
EyePoint Pharmaceuticals is developing the EYP-1901 treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy. Q2 2023 earnings show a decrease in net revenue, but
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
07:00am, Wednesday, 09'th Aug 2023
WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates
09:42am, Wednesday, 02'nd Aug 2023
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $0.41. This compares to loss of $0.52 per share a year ago.
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
07:00am, Wednesday, 26'th Jul 2023
WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w
EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
07:00am, Wednesday, 31'st May 2023
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients wi
EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success
08:00am, Tuesday, 30'th May 2023
EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22. E
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call Transcript
11:48pm, Wednesday, 03'rd May 2023
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?
05:20am, Thursday, 20'th Apr 2023
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
08:00am, Monday, 27'th Feb 2023
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023
07:00am, Thursday, 23'rd Feb 2023
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
01:33pm, Monday, 14'th Nov 2022
Analysts say these are penny stocks to buy. Do you agree?
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
08:00am, Monday, 07'th Nov 2022
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call Transcript
01:58pm, Wednesday, 02'nd Nov 2022
Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
09:48am, Wednesday, 02'nd Nov 2022
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
